During the last session, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s traded shares were 0.67 million, with the beta value of the company hitting -0.66. At the end of the trading day, the stock’s price was $4.12, reflecting an intraday loss of -6.58% or -$0.29. The 52-week high for the AMLX share is $19.95, that puts it down -384.22 from that peak though still a striking 61.65% gain since the share price plummeted to a 52-week low of $1.58. The company’s market capitalization is $282.42M, and the average intraday trading volume over the past 10 days was 0.7 million shares, and the average trade volume was 1.43 million shares over the past three months.
Amylyx Pharmaceuticals Inc (AMLX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. AMLX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.59.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Amylyx Pharmaceuticals Inc (AMLX) registered a -6.58% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.58% in intraday trading to $4.12, hitting a weekly high. The stock’s 5-day price performance is -19.84%, and it has moved by -27.46% in 30 days. Based on these gigs, the overall price performance for the year is -72.01%. The short interest in Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) is 1.45 million shares and it means that shorts have 1.0 day(s) to cover.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 54.22% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $11 respectively. As a result, AMLX is trading at a discount of -166.99% off the target high and 2.91% off the low.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
Statistics show that Amylyx Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Amylyx Pharmaceuticals Inc (AMLX) shares have gone up 151.22% during the last six months, with a year-to-date growth rate less than the industry average at -712.86% against 16.40. In the rating firms’ projections, revenue will decrease -76.88% compared to the previous financial year.
As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 108.45M and 88.64M respectively. In this case, analysts expect current quarter sales to shrink by -100.00% and then drop by -100.00% in the coming quarter.
While earnings are projected to return -712.86% in 2024.
AMLX Dividends
Amylyx Pharmaceuticals Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
Amylyx Pharmaceuticals Inc insiders own 14.30% of total outstanding shares while institutional holders control 82.51%, with the float percentage being 96.28%. VANGUARD GROUP INC is the largest shareholder of the company, while 156.0 institutions own stock in it. As of 2024-06-30, the company held over 4.22 million shares (or 6.2251% of all shares), a total value of $8.03 million in shares.
The next largest institutional holding, with 3.34 million shares, is of AQR CAPITAL MANAGEMENT LLC’s that is approximately 4.9237% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.35 million.
